These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 26855028)

  • 1. Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
    Ryan JM; Wasser JS; Adler AJ; Vella AT
    Expert Opin Biol Ther; 2016; 16(5):655-74. PubMed ID: 26855028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.
    Hamilton G; Rath B
    Expert Opin Biol Ther; 2017 Apr; 17(4):515-523. PubMed ID: 28274143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversing T-cell Dysfunction and Exhaustion in Cancer.
    Zarour HM
    Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors side effects and management.
    Kourie HR; Klastersky J
    Immunotherapy; 2016 Jun; 8(7):799-807. PubMed ID: 27349979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB.
    Manso T; Kushwaha A; Abdollahi N; Duroux P; Giudicelli V; Kossida S
    Front Immunol; 2023; 14():1129323. PubMed ID: 37215135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy.
    Riller Q; Varthaman A; Sibéril S
    Adv Exp Med Biol; 2020; 1277():127-141. PubMed ID: 33119870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
    Fong L; Small EJ
    J Clin Oncol; 2008 Nov; 26(32):5275-83. PubMed ID: 18838703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy.
    Zhao H; Li Y; Wei D; Luo H
    J Immunol Res; 2018; 2018():3673295. PubMed ID: 30406152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle.
    Manieri NA; Chiang EY; Grogan JL
    Trends Immunol; 2017 Jan; 38(1):20-28. PubMed ID: 27793572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms.
    Sun L; Chen L; Li H
    Int Immunopharmacol; 2019 Feb; 67():160-175. PubMed ID: 30553199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges.
    Diesendruck Y; Benhar I
    Drug Resist Updat; 2017 Jan; 30():39-47. PubMed ID: 28363334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges.
    Teng F; Kong L; Meng X; Yang J; Yu J
    Cancer Lett; 2015 Aug; 365(1):23-9. PubMed ID: 25980820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
    Cousin S; Italiano A
    Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies.
    Sasso E; D'Avino C; Passariello M; D'Alise AM; Siciliano D; Esposito ML; Froechlich G; Cortese R; Scarselli E; Zambrano N; Nicosia A; De Lorenzo C
    MAbs; 2018 Oct; 10(7):1060-1072. PubMed ID: 29995563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies.
    Barnhart BC; Quigley M
    Immunol Cell Biol; 2017 Apr; 95(4):340-346. PubMed ID: 27974746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.